QVA
- 产品代码
- QVA
- 器械名称
- Fludeoxyglucose F18-Guided Radiation Therapy System
- 管理类别
- 第 2 类(Class II)
- 21 CFR 条款
- 21 CFR 892.5060
- FDA 专业组
- Radiology
- 上市路径
- 需提交 510(k) 上市前通告
- 该代码近三年的 510(k)
- 1 件
- 其中 Summary 已存档
- 1 份,可直接下载
- FDA 历史累计 510(k)
- 2 件(全部年份;本站只收录近三年的明细)
FDA 分类定义
A fludeoxyglucose F18-guided radiation therapy system is a device that combines the functionality of an emission computed tomography detection system and a linear accelerator. The device is intended for use with approved fludeoxyglucose F18. The emission computed tomography detection system acquires images of positron-emitting fludeoxyglucose F18 for the purpose of guiding the delivery of megavoltage X-rays for oncologic treatment with radiation therapy using an FDA cleared, authorized, or approved linear accelerator.
该代码近三年的 510(k)(1 件)
| 510(k) 号 | 批准日期 | 申请人 | 器械名称 | 摘要 |
|---|---|---|---|---|
| K252071 | 2025-12-18 | Reflexion Medical, Inc. | RefleXion Medical Radiotherapy System, Reflexion X2 |
FDA 官方分类页: QVA
分类与上市路径以 FDA 现行公告为准。本页数据来自 openFDA(CC0 公有领域),不构成注册策略建议。